bluebird bio, Inc. (NASDAQ:BLUE – Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 49,370,000 shares, an increase of 20.0% from the August 15th total of 41,140,000 shares. Based on an average daily trading volume, of 7,240,000 shares, the short-interest ratio is presently 6.8 days.
bluebird bio Trading Down 13.3 %
BLUE stock traded down $0.08 during mid-day trading on Tuesday, hitting $0.50. The stock had a trading volume of 6,507,534 shares, compared to its average volume of 7,738,188. bluebird bio has a 1-year low of $0.48 and a 1-year high of $5.53. The company has a fifty day moving average of $0.88 and a 200 day moving average of $1.01. The stock has a market capitalization of $54.76 million, a price-to-earnings ratio of -0.68 and a beta of 0.75.
Hedge Funds Weigh In On bluebird bio
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLUE. Vanguard Group Inc. increased its stake in shares of bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after purchasing an additional 1,723,081 shares during the last quarter. Ghisallo Capital Management LLC acquired a new position in bluebird bio during the fourth quarter worth $4,347,000. Vestal Point Capital LP bought a new position in bluebird bio during the fourth quarter valued at about $2,967,000. HBK Investments L P acquired a new stake in shares of bluebird bio in the fourth quarter worth about $2,070,000. Finally, AQR Capital Management LLC boosted its stake in shares of bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after acquiring an additional 1,013,144 shares in the last quarter. Institutional investors own 87.43% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on bluebird bio
bluebird bio Company Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Read More
- Five stocks we like better than bluebird bio
- What Investors Need to Know to Beat the Market
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- P/E Ratio Calculation: How to Assess Stocks
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
- What is a Low P/E Ratio and What Does it Tell Investors?
- What Buybacks and Lower Rates Could Mean for Restaurant Brands
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.